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Background: DNA damage repair genes JWA, XRCC1 and BRCA1 were associated with clinical outcomes and could
convert the response to the cisplatin-based therapy in some carcinomas. The synergistic effects of JWA, XRCC1 and BRCA1
mRNA expression on personalized therapy remain unknown in advanced esophageal squamous cell carcinoma (ESCC).
Methods: We employed quantitative real-time polymerase chain reaction (qPCR) to determine the expression of JWA,
XRCC1 and BRCA1 mRNA in paraffin-embedded specimen from 172 patients with advanced ESCC who underwent the
first-line cisplatin-or docetaxel-based treatments.
Results: High JWA or XRCC1mRNA expression was correlated with longer median overall survival (mOS) in all the
patients (both P < 0.001) or in subgroups with different regimens (all P < 0.05), but not correlated with response rate (RR,
all P > 0.05). Multivariate analysis revealed that high JWA (HR 0.22; 95% CI 0.13-0.37; P < 0.001) or XRCC1 (HR 0.36; 95% CI
0.21-0.63; P < 0.001) mRNA expression emerged as the independent prognostic factors for ESCC patients in this cohort.
But no significant difference in prognostic efficacy was found between JWA plus XRCC1 and JWA alone through ROC
analysis. Further subgroup analysis showed cisplatin-based treatments could improve mOS of patients with low JWA
expression (P< 0.05), especially in those with low BRCA1 expression simultaneously (P< 0.001); while in patients with high
JWA expression, high BRCA1 mRNA expression was correlated with increased mOS in docetaxel-based treatments (P= 0.044).
Conclusion: JWA, XRCC1and BRCA1 mRNA expression could be used as predictive markers in molecular staging
for personalized therapy in patients with advanced ESCC who received first-line cisplatin- or docetaxel-based treatments.Background
Esophageal cancer was the eighth most common cancer
with rapidly increasing incidence and the sixth leading
cause of cancer-related death worldwide as estimated in
2008 [1]. Despite the progress in the multimodal therapy
with the combination of operation, radiotherapy and
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based on molecular staging might help to determine the
optimal regimen for the right patients on the right time,
which would contribute to improving clinical outcomes
and limiting toxic and side effects [4]. Although some
molecular markers have been identified for personalized
treatment of esophageal cancer, such as cisplatin related
markers [breast cancer susceptibility gene 1 (BRCA1) and
excision repair cross-complementing 1 (ERCC1)], 5-FU re-
lated markers [dihydropyrimidine dehydrogenase (DPD)
and thymidylatesynthase (TS)] and docetaxel related
markers (BRCA1) [5-7], the molecular backgrounds remainle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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esophageal cancer systematically.
In our previous researches, JWA was identified as
a novel microtubule-associated gene which encoded
the ADP-ribosylation-like factor 6 interacting protein 5
(ARL6ip5) involved in cell oxidative stress, differenti-
ation and apoptosis [8-10]. Also, JWA was found to
regulate cancer cells migration via MAPK cascades and
suppress the ability of adhesion, invasion and metastasis
by integrin alphaVbeta3 signaling [11,12]. Recently, we
confirmed that JWA was a base excision repair (BER)
protein which could regulate X-ray repair cross comple-
ment group 1(XRCC1) and participated in the DNA
damage repair pathway through stabilizing BER protein
complex to facilitate the repair of DNA single-strand
breaks (SSB) [13]. The DNA repair protein XRCC1 inter-
acted with enzymatic components which include PARP-1,
DNA polymerase β, APE1, PNK, PCNA and DNA ligase
III in BER pathway [14-19]. Single nucleotide polymor-
phisms (SNPs) of XRCC1 gene acted as a risk factor might
be a valuable genetic marker for chemotherapy in various
cancers containing esophageal cancer [20-22]. Our group
has demonstrated the possibility of JWA participating in
tailored therapy of tumor for its novel function as regula-
tor of XRCC1. In previous clinical studies, we confirmed
that the expressions of JWA and XRCC1 protein were sig-
nificant prognostic and predictive biomarker in hepatocel-
lular carcinoma and gastric cancer [23-25]. Also, the other
DNA repair proteinBRCA1 which was involved in nucleo-
tide excision repair (NER) and DNA double single break
repair (DSBR) pathway was found to participate in the in-
verse resistance to cisplatin- or docetaxel-based treat-
ments in patients with esophageal cancer [7,26].
However, whether combination of JWA, XRCC1 and
BRCA1 mRNA expressions could be used as prognostic
markers in molecular staging for tailored therapy in ESCC
needs to be determined in clinic urgently. In present
study, the aim is to investigate the prognostic and predict-
ive roles of JWA/XRCC1 mRNA expressions and to ex-
plore the synergistic effect of JWA/XRCC1/BRCA1mRNA
expression on molecular staging in personalized therapy




A total of 172 patients enrolled in the study were all histo-
logically confirmed to be locally advanced or metastatic
ESCC (stage II-IV) and had available paraffin-embedded
tumor material for molecular analysis. They all had meas-
urable lesions with a better Eastern Cooperative Oncology
Group performance status (PS; 0 to 2). Among them, 81
patients with metastatic or with surgically unresectable
disease who couldn’t tolerate radiotherapy underwentcisplatin- or docetaxel-based chemotherapy as the first-line
treatment. The chemotherapy regimens included cisplatin-
based regimens (cisplatin 25 mg/m2 on day 1-3 plus 5-
fluorouracil 500 mg/m2 on day 1-5) and docetaxel-based
regimens (docetaxel 60-75 mg/m2 plus 5-fluorouracil
500 mg/m2 on day 1-5). Chemotherapy was repeated every
3-4 weeks for a maximum of six cycles unless patients had
disease progression or in unsupportable adverse reactions.
The other 91 patients with locally advanced disease under-
went cisplatin or docetaxel-based concurrent chemoradio-
therapy (CCRT) or radiotherapy alone as the first-line
treatment. CCRT consisted of chemotherapy and concur-
rent thoracic radiotherapy. The chemotherapy regimens
comprised weekly cisplatin (25 mg/ m2 on day 1 per week)
plus 5-fluorouracil (300 mg/ m2 on day 1-3 per week) or
docetaxel (25 mg/ m2 on day 1 per week) plus 5-fluorouracil
(300 mg/m2 on day 1-3 per week) for 5 weeks. CT simula-
tion and 3 D treatment planning were used in the concur-
rent thoracic radiotherapy with radiation dose of 50-60
grays (Gy) over 5 weeks (2 Gy/fraction per day, 5 fractions
per week). Barium swallow and computed tomography scans
were utilized in baseline and restaging assessment every
2 cycle of chemotherapy or 4 weeks after radiotherapy.
The institutional approval was obtained from ethics
committee of Huai’an First Hospital of Nanjing Medical
University and all patients signed their informed consent
for the use of tissue material in this translational research.
qPCR analysis for JWA, XRCC1 and BRCA1 mRNA expression
We assessed JWA, XRCC1 and BRCA1 mRNA expres-
sion in paraffin-embedded tumor specimens obtained by
biopsy under endoscope from 172 patients as described
in previous study [7]. Before RNA preparation, micro-
dissection was performed to ensure serial sections of
7-mm thickness with more than 80% of tumor cells. The
pellet of micro-dissected cells was resuspended in RNA
lysis buffer supplemented with proteinase K after paraffin
was removed by xylene. RNA was then extracted with
phenol-chloroform-isoamyl alcohol and precipitated with
isopropanol in the presence of glycogen and sodium acet-
ate. Subsequently RNA was treated with DNase to avoid
genomic DNA contamination. The M-MLV reverse tran-
scriptase was used to synthesize cDNA. Template cDNA
was amplified with specific primers for JWA, XRCC1,
BRCA1 and β-actin as follows: 5′-GGAGGAGTCATTG
TGGTGC-3′ (forward) and 5′-GAAGTCTCAGGGATG
CGTG-3′ (reverse) for JWA; 5′-CTTTGTGGAGGTGCT
AGTGG-3′ (forward) and 5′-ATGGCGAGTCCTTGC
TGT-3′ (reverse) for XRCC1; BRCA1 5′-GGCTATCCTC
TCAGAGTGACATTTTA-3′ (forward) and 5′-GCTTTA
TCAGGTTATGTTGCATGGT-3′ (reverse) for BRCA1,
5′-TGAGCGCGGCTACAGCTT -3′ (forward) and 5′-TC
CTTAATGTCACGCACGATTT -3′ (reverse) for β-actin.
Gene expression was quantified by quantitative real-time
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Sequence Detection System (Applied Biosystems, Foster
City, CA) and the qPCR products were detected by fluoro-
chrome dye SYBR Premix Ex TaqTM (TaKaRa, Japan).
Each sample was assayed in triplicate with RNase-free
water as negative control and commercial RNA as positive
control. Relative gene expression quantification was con-
ducted according to the comparative quantification cycle
(Cq) method using β-actin as an endogenous control and
commercial RNA controls (human lung and liver RNA;
Strata gene, La Jolla, CA, USA) as calibrators. In all exper-
iments, only triplicates with a standard deviation (SD) of
the Cq value < 0.30 were accepted. Final values were deter-
mined by the formula 2-△△Cq [=2- (Cq sample - Cq calibrator)].
All experiments were conducted in the Department of
Molecular Cell Biology and Toxicology, Nanjing Medical
University (Nanjing, China).
Study design and statistical analysis
The primary endpoint of this study was to examine the
potential prognostic and predictive roles of JWA/XRCC1
mRNA expressions and to explore the synergistic effect
of JWA/XRCC1/BRCA1mRNA expression on overall
survival and clinical responses in ESCC patients treated
with cisplatin- or docetaxel-based regimens in the first-
line. Overall survival was calculated from the date of
pathologic diagnosis to the date of death or last follow-
up or death from any cause. The clinical response was
assessed according to the Response Evaluation Criteria
Evaluation in Solid Tumors (RECIST) [27]. The Tumor
Node Metastasis (TNM) system was used to classify the
tumor stage. Progression-free survival was not examined
because we could not get exact time of progress-free
survival of the patients who did not receive further assess-
ments of disease after fist-line treatment in the present
retrospective study. The median value was employed as
the cut-off points [7,28]. Samples with mRNA expression
above the median were considered as high expression,
whereas those with value below or equal to the median as
low expression. The distributions of patients were re-
ported with demographic, clinical and biological charac-
teristics. The absolute frequencies and percentages were
used to depict qualitative variables, and the median values
and ranges were used to describe quantitative variables.
The normality of quantitative variables was analysed by
the Kolmogorov-Smirnov test and compared with the
Mann-Whitney U test. The potential association between
clinical characteristics, response and gene expression
levels were compared with two-sided chi-square test or
Fisher exact test. The distributions of OS were ascertained
to probe for the significance by using Kaplan-Meier
method and compared with the two-sided log-rank test. A
multivariate Cox regression analysis with hazard ratios
(HR) and 95% confidence intervals (95% CI) were used toassess the association between each potential prognostic
factor and survival. The time-dependent ROC curve ana-
lysis for censored data and the area under the Curve
(AUC) of the ROC curves were used to analyse the pre-
dictive value of the parameters [29]. Statistical significance
was considered to be P ≤ 0.05. Statistical analyses were
performed with the Statistical Package for the Social




Clinical data and paraffin-embedded samples from the
primary tumors were collected from 172 ESCC patients
treated with cisplatin- or docetaxel-based chemother-
apy/chemoradiotherapy in our center. Successful ampli-
fication of three genes of JWA, XRCC1 and BRCA1 was
achieved in 145 specimens. The median age was 62 (44-
84 years) and 92 patients were male. The majority of pa-
tients had PS 0-1. Among them, 73 patients treated with
chemotherapy had stage III–IV and other 72 patients
treated with chemoradiotherapy or radiotherapy alone
had stage II–III at the time of diagnosis. The clinical re-
sponse rates (RR) were 68.5% and 83.3% in the two
treatment groups, separately. After a median follow up
period of 52.0 months (range 19.0-100.0), the mOS was
13.0 months (95% CI: 11.3-14.7) in chemotherapy group;
while the mOS was 13.5 months (95% CI: 11.3-15.7)
after a median follow-up period 48.0 months (range
20.0-100.0) in chemoradiotherapy group. All patient
characteristics were shown in Table 1.
Genes’ mRNA expression levels and treatment outcomes
The median mRNA expression levels were 2.4 (range
0.0002-126.0) for JWA, 8.6(range 0.03-1410.4) for XRCC1
and 11.4 (range 0.4-70.0) for BRCA1. JWA mRNA expres-
sion was significantly associated with clinical features in-
cluding patients’ gender and tumor differentiation grade.
The JWA expression was higher in the females than the
males (P = 0.025) and positively correlated with tumor
differentiation grade stage (G stage, P = 0.047). There was
no other association between clinical features and JWA,
XRCC1 or BRCA1 mRNA levels (all P > 0.05) (Table 2).
As to correlations of three genes, we observed the positive
correlation between JWA and XRCC1 mRNA expression
(Spearman’s test 0.67; P < 0.001) while BRCA1 was not
correlated with JWA or XRCC1 expression (Spearman’s
test 0.007, -0.131; P = 0.937, 0. 115).
Clinical outcomes according to JWA, XRCC1 and
BRCA1 mRNA expression were shown in Table 3. In the
whole cohort, patients with high JWA mRNA expression
had an increased median overall survival (mOS, 19.0 vs.
8.0 months, P < 0.001, Figure 1A) compared with those
with low JWA expression. Similarly, patients with high
Table 1 Patient characteristics of advanced (stage II–IV) esophageal cancer patients
Chemotherapy Chemoradiotherapy
Characteristics All patients Cis/ 5-Fu Doc/ 5-Fu Radio alone Cis/ 5-Fu/ Radio Doc/ 5-Fu/ Radio
Patients, No. (%) 145 (100) 35 (24.1) 38 (26.2) 12 (8.3) 30 (20.7) 30 (20.7)
Age, y median (range) 62 (44-84) 60 (48-81) 61 (45-78) 68 (44-83) 63 (45-74) 61 (52-84)
Sex (%)
Males 92 (63.4) 25 (27.2) 24 (26.1) 6 (6.5) 19 (20.6) 18 (19.6)
Females 53 (36.6) 10 (18.9) 14 (26.4) 6 (11.3) 11 (20.8) 12 (22.6)
ECOG, PS (%)
0-1 133 (91.7) 32 (24.1) 34 (25.6) 12 (9.0) 27 (20.3) 28 (21.0)
2 12 (8.3) 3 (25.0) 4 (33.3) 0 (0.0) 3 (25.0) 2 (16.7)
TNM stage (%)
II 28 (19.3) 0 (0.0) 0 (0.0) 12 (42.9) 15 (53.6) 1 (3.5)
III 47 (32.4) 2 (4.2) 1 (2.1) 0 (0.0) 15 (31.9) 29 (61.7)
IV 70 (48.2) 33 (47.1) 37 (52.8) 0 (0.0) 0 (0.0) 0 (0.0)
G stage (%)
G1 20 (13.8) 4 (20.0) 3 (15.0) 8 (40.0) 3 (15.0) 2 (10.0)
G2 90 (62.1) 25 (27.7) 24 (26.7) 3 (3.3) 24 (26.7) 14 (15.6)
G3 35 (24.1) 6 (17.1) 11 (31.4) 1 (2.9) 3 (8.6) 14 (40.0)
JWA median (range) 2.4(0.0002-126.0) 3(0.001-29.1) 2.2(0.0002-126.0) 3.9(0.3-67.8) 3.2(0.0014-50.1) 2.5(0.001-34.8)
XRCC1 median (range) 8.6(0.03-1410.4) 11.3(0.04-190.7) 5.5(0.03-211.7) 11.9(0.9-327.6) 9(0.1-1410.4) 7.3(0.03-64.3)
BRCA1 median (range) 11.4(0.4–70.0) 10.2(0.4–70.0) 10.9(0.6–44.9) 10.3(0.4–44.2) 11.4(1.2-62.9) 12.2(2.0–58.9)
Response rate (CR + PR), No. (%) 50 (68.5) 60 (83.3)
Median OS (months, 95%CI) 13 (11.3-14.7) 13.5 (11.3-15.7)
Cis = cisplatin; 5-Fu = 5-fluorouracil; Doc = docetaxel; ECOG = Eastern Cooperative Oncology Group; PS = Performance status; G = differentiation grade;
CR = complete response; PR = partial response; OS = overall survival; CI = confidence interval; y = years.
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(19.0 vs. 9.0 months, P < 0.001; Figure 1B) in comparison
with those with low XRCC1 expression. Conversely, no
significant difference was observed in mOS (15.0 vs.
14.0 months, P = 0.429; Figure 1C) of patients according
to BRCA1 expression levels. Moreover, there was no dif-
ference in term of clinical RR according to the expression
of JWA (83.3% vs. 68.5%, P = 0.052), XRCC1 (83.3% vs.
68.5%, P = 0.052) and BRCA1 (78.7% vs. 71.8%, P = 0.267).
To further assess the synergistic efficacy of JWA and
XRCC1 mRNA expression on survival, the patients were
then stratified into 4 distinct groups depending on gene
expression of JWA and XRCC1: both high, JWA high/
XRCC1 low, JWA low/ XRCC1 high and both low. It
was shown that patients with both high or JWA high/
XRCC1 low (mOS were 21.0 and 17.0 months) had a
better outcome of survival than in the other 2 groups
(mOS were 10.0 and 8.0 months), which indicated that
JWA mRNA expression mainly affected overall survival
of patients in this cohort (Figure 2A, Additional file 1:
Table S1). To further evaluate the prognostic efficacy of
JWA, time-dependent ROC analysis was carried out forthe censored data. The combination of clinical risk score
(TNM stage and G stage) and JWA or XRCC1 or JWA
plus XRCC1 contributed much more than clinical risk
score alone. However, JWA plus XRCC1 was not super-
ior to JWA which contributed much more than XRCC1
(Figure 2B, Additional file 1: Table S2). For example, the
AUC at year 3 was 0.765 for the combination of clinical
risk score with JWA plus XRCC1 and 0.769 for the com-
bination of clinical risk score with JWA, which showed
that JWA plus XRCC1 mRNA expression were not bet-
ter than JWA alone as a predictor for survival of patients
with ESCC in present study.
Treatment outcomes according to regimens or gene
expression levels
In the further subgroup analysis stratified by regimens,
high JWA or XRCC1 mRNA expression was all correlated
with longer mOS (all P < 0.05) but not correlated with RR
(all P > 0.05) in each subgroup with cisplatin- or docetaxel-
based chemotherapy/chemoradiotherapy (Additional file 1:
Table S3, S5 andAdditional file 2: Figure S1, S2). In the
chemotherapy group stratified by gene expression, patients
Table 2 Clinical characteristics associated with JWA, XRCC1 and BRCA1 mRNA expression levels
JWA level XRCC1 level BRCA1 level Overall survival
Characteristics Low High P value Low High P value Low High P value mOS (95%CI) P value
Age, y
≤62 39 36 40 35 37 38 13.0(11.3-14.8)
>62 34 36 0.741 33 37 0.456 37 33 0.671 13.0(10.0-16.0) 0.805
Gender
Males 53 39 52 40 47 45 12.0(10.1-13.9)
Females 20 33 0.025 21 32 0.053 27 26 0.987 16.0(13.4-18.6) 0.007
ECOG, PS
0-1 66 67 68 65 67 66 14.0(12.3-15.4)
2 6 6 0.98 5 7 0.53 7 5 0.597 6.0(4.9-7.8) <0.001
TNM stage
II 12 16 14 14 18 10 14.0(11.9-16.1)
III 25 22 25 22 22 25 10.0(8.3-11.7) 0.096
IV 36 34 0.666 34 36 0.886 34 36 0.290 14.0(11.4-14.6) 0.656
G stage
G1 5 15 7 13 9 11 18.5(15.8-21.2)
G2 48 42 47 43 50 40 13.0(11.4-14.7) 0.061
G3 20 15 0.047 19 16 0.328 15 20 0.375 9.0(6.7-11.3) 0.005
mOS =median overall survival; y = years; G = differentiation grade; ECOG = Eastern Cooperative Oncology Group; PS = performance status.
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when treated with cisplatin-based chemotherapy compared
to docetaxel-based chemotherapy (10.0 vs. 8.0 months,
P = 0.015; Figure 3A and Additional file 1: Table S4). In the
chemoradiotherapy group, cisplatin-based chemoradiother-
apy was the best choice of treatment for patients with
low JWA expression compared with docetaxel-based
chemoradiotherapy or radiotherapy alone [mOS were 11.0,
7.0 (P = 0.001) and 7.5 months (P = 0.537), respectively;
Figure 3B and Additional file 1: Table S4]. However, no sig-
nificant difference of mOS was found in patients with high
JWA or low XRCC1 or high XRCC1 mRNA expression
between cisplatin-based and docetaxel-based treatments
(all P > 0.05; Figure 3C, D and Additional file 1: Table S4,
S6, Additional file 2: Figure S3). Low BRCA1 mRNATable 3 Treatment outcomes according to genes expression l
RR, N (%)
Gene Level No. CR + PR SD +
JWA Low 73 68.5 31.5
High 72 83.3 16.7
XRCC1 Low 73 68.5 31.5
High 72 83.3 16.7
BRCA1 Low 74 79.7 20.3
High 71 71.8 28.2
mOS =median overall survival; RR = response rate; CI = confidence interval; CR = com
PD = progress disease.expression correlated with increased mOS (P = 0.001 and
P = 0.003, respectively) in cisplatin-based chemotherapy or
chemoradiotherapy group and inversely correlated with de-
ceased mOS (P = 0.020 and P = 0.048, respectively) in
docetaxel-based chemotherapy or chemoradiotherapy group,
which was in line with the results shown in the previous
research [7] (Additional file 1: Table S7, S8 and Additional
file 2: Figure S4, S5).
Prognostic value of combining JWA with BRCA1 mRNA
expression according to regimens
For effects of JWA or BRCA1 mRNA expression on sur-
vival of ESCC in term with regimens, the prognostic
value of combination with the two genes was further in-
vestigated in subgroup analysis according to treatmentsevels
mOS (months)







plete response; PR = partial response; SD = stable disease;
Figure 1 Median OS in total 145 advanced and metastasis esophageal cancer patients (stage II–IV) according to the mRNA expression levels.
(A) JWA mRNA expression. (B) XRCC1 mRNA expression. (C) BRCA1 mRNA expression.
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cisplatin-based treatment brought a better survival (20.0
vs. 8.0 months; P<0.001) to patients with low JWA/ low
BRCA1 mRNA expression, whereas docetaxel-based treatment
prolonged survival of those with high JWA/high BRCA1
mRNA expression (18.0 vs. 12.0 months; P = 0.044). No
significant difference of survival was observed in the sub-
groups with one gene high (JWA or BRCA1 high) be-
tween cisplatin-based and docetaxel-based treatments (all
P > 0.050).Univariate and multivariate analyses
Univariate analysis demonstrated that significant associ-
ation was observed between mOS and PS (P < 0.001),
gender (P = 0.007), tumor differentiation grade stage
(P = 0.005), JWA (P < 0.001) or XRCC1 (P < 0.001) mRNA
expression in the whole cohort (Tables 2 and 3). Cox
proportional hazard analysis revealed that high JWA
(HR 0.22; 95% CI 0.13-0.37; P < 0.001) or high XRCC1
mRNA expression (HR 0.36; 95% CI 0.21-0.63; P < 0.001)




















Figure 2 Combined effects of JWA/XRCC1 mRNA expression. (A) Median OS according to the combination of JWA/XRCC1 expression levels.
(B) Time-dependent ROC analyses for the clinical risk score (TNM stage and G stage), combination of JWA or XRCC1.
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grade (HR 1.45; 95% CI 1.06-1.97; P = 0.019) emerged
as higher risk for mortality associated with decreased
mOS (Table 4).
Discussion
This study was the first to detect the prognostic roles and
synergistic effects of JWA/XRCC1/BRCA1 mRNA expres-
sion in paraffin-embedded tumor tissues on molecular sta-
ging for personalized therapy of advanced ESCC who
received cisplatin- or docetaxel-based treatments.
In our study, JWA mRNA expression was significantly
associated with patients’ gender in this cohort, which
showed that median JWA expression level was higher
in females than in males. In the previous studies, the
alcohol and tobacco consumption which were found sig-
nificantly higher in males than in females had the syner-
gistic effects on the development of ESCC [30-32]. Both
risk factors were proved to take part in the dysregulation
of cell cycle, apoptosis and DNA repair [33-35]. JWA, as
a DNA repair gene and anti-oncogene [24], might be
correlated with the consumption of alcohol and tobacco
in ESCC patients. In addition, estrogen can regulate
transcription of genes associated with cell survival and
proliferation by activating the estrogen receptor related
pathways [36], which might explain the difference of
JWA expression between males and females if JWA was
involved in these pathways. However, the relationship
between JWA and the alcohol/tobacco consumption or
estrogen was not clear and need to be further studied.
Also, we found that JWA expression level was positivelycorrelated with tumor differentiation grade in ESCC pa-
tients. Though the loss of JWA expression has been dis-
covered to inhibit the cell differentiation and cause more
malignant phenotypes [8,23,37], it was still ambiguous
whether JWA could be the important regulatory factor
in differentiation-related pathways including JAK-STAT,
Notch and Wnt signaling pathways [38-40]. Further
studies should be carried out to discover whether and
how JWA participated in these pathways.
In this study, high JWA or XRCC1 mRNA expression
was correlated with longer overall survival in all the pa-
tients or in subgroups treated with different regimens
and emerged as the independent prognostic factors for
ESCC patients in this cohort. These findings were in
agreement with the results in the gastric, hepatocellular
and bladder carcinomas [23,24,41]. Increasing evidences
implicated the role of JWA on oncogenic and metastatic
phenotypes in several human cancers. Downregulation
of JWA was found to be crucial for the invasion and me-
tastasis of human tumor through elevated FAK expres-
sion, the induction of RhoA and MMP-2 activation
[11,24,25]. In addition, JWA has significant predictive
power for its correlation with tumor differentiation in
the present study, which was known as an important
factor for tumor progression. XRCC1 protein was
deemed as a scaffold in the process of BER binding the
DNA and recruiting other repair components after rec-
ognizing DNA breaks [14-19]. XRCC1 gene might be a
valuable genetic marker for chemotherapy in various
cancers as mentioned above. In present study, predictive
roles of JWA and XRCC1 on survival with a similar
Figure 3 Median OS in low and high JWA expression levels according to different regimens. (A) Chemotherapy in low JWA expression.
(B) Chemoradiotherapy in low JWA expression. (C) Chemotherapy in high JWA expression. (D) Chemoradiotherapy in high JWA expression.
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the two genes. JWA was found to cause XRCC1 tran-
scription through increasing the affinity of E2F1 for
binding to the XRCC1 promoter via MAPK signaling
pathway and maintain the stability of the XRCC1 protein
through inhibiting the ubiquitin-proteasome pathway
[13]. We revealed that JWA alone was sufficient to pre-
dict the survival of advanced ESCC compared with com-
bining JWA with XRCC1 according to ROC analysis,
although this result was not consistent with the pub-
lished data that combining JWA with XRCC1 had the
synergistic effect on prognosis in gastric cancer [23].DNA repair proteins were proved to play important
roles in the process of repairing DNA damage caused
by chemotherapeutics [5-7]. In this study, low expression
of JWA mRNA was significantly correlated with in-
creased mOS in patients treated with cisplatin-based
regimens but not in those treated with docetaxel-based
regimens though JWA was identified as microtubule-
associated protein, which was consistent with the
current evidence for the predictive value of JWA in re-
sectable gastric cancer that underwent platinum-based
adjuvant chemotherapy [23,25,42]. Also, JWA as a new
BER protein was found to protect cells with induced DNA
Figure 4 Median OS according to the cis-based or doc-based treatments in different groups. (A) Low JWA and low BRCA1 mRNA expression.
(B) Low JWA and high BRCA1 mRNA expression. (C) High JWA and low BRCA1 mRNA expression. (D) High JWA and high BRCA1 mRNA expression.
Wei et al. BMC Cancer  (2015) 15:331 Page 9 of 11damage through upregulating XRCC1 and downregulating
PARP-1, which might explain the predictive value of JWA
to cisplatin sensitivity [13]. However, the predictive role of
XRCC1 on the cisplatin sensitivity was not observed in
this cohort. Seemingly, JWA mRNA expression was better
than XRCC1 to be the prognostic factor for ESCC patients
who received cisplatin-based treatment. Although previ-
ous researches had discovered some DNA repair proteins
associated to the damage caused by radiation in vitro, we
didn’t find effects of JWA on radiotherapy sensitivity in
this study [43-45].BRCA1 mRNA expression level was observed to be a
valid predictor of inverse sensitivity to cisplatin or doce-
taxel in advanced ESCC, which was also shown in our
previous study [7]. For effects of JWA or BRCA1 mRNA
expression on survival of ESCC in terms with regimens,
the synergistic effects of the two gene expression on
cisplatin or docetaxel-based treatments were further
explored. The patients with low JWA/low BRCA1 ex-
pressing benefited mostly from cisplatin-based treat-
ment, and those with high JWA/high BRCA1 expression
benefited mostly from docetaxel-based treatment. From
Table 4 Multivariate cox regression analysis of clinical
characteristics and JWA, XRCC1 and BRCA1 expression
associated with survival
Clinical variables HR 95%CI P value
Gender (females vs. males) 0.83 0.56-1.22 0.349
ECOG, PS (0-1 vs. 2) 0.70 0.59-1.43 0.701
TNM stage (II vs. III or III vs. IV) 0.57 0.74-1.18 0.567
G stage (G1 vs. G2 or G2 vs. G3) 1.45 1.06-1.97 0.019
JWA (low vs. high) 0.22 0.13-0.37 <0.001
XRCC1 (low vs. high) 0.36 0.21-0.63 <0.001
BRCA1 (low vs. high) 1.14 0.80-1.62 0.485
HR = hazard ratios; y = years; G = differentiation grade; RR = response rate;
CI = confidence interval.
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high BRCA1 expression who could not benefit from
cisplatin- or docetaxel-based treatment. Combining JWA
with BRCA1 mRNA expression might be better than sin-
gle gene expression currently used in personalized therapy
for ESCC patients. It seems that combined NER and BER
pathways are more significant to predict therapy outcome
than single pathway [13,26].
Several limitations needed to be considered and clarified
in this study, which included unplanned and retrospective
analysis, lacking of validation group and relatively small
number of patients in the subgroups. However, the prog-
nostic and predictive roles of JWA/ XRCC1/BRCA1 mRNA
expression were firstly proved in personalized therapy for
patients with advanced ESCC treated with cisplain- or
docetaxel-based regimens and indicated the need to further
validate in prospective adequately designed clinical trials.
Conclusions
In this study, we demonstrated that high JWA or XRCC1
mRNA expression emerged as the independent prognostic
factors for ESCC patients and JWA alone was sufficient to
predict the survival compared with combining JWA with
XRCC1. Also, we further proved the synergistic effects of
combining JWA with BRCA1 expression on cisplatin or
docetaxel-based treatments. In summary, JWA, XRCC1
and BRCA1 mRNA expression as predictive markers
could be used in molecular staging for personalized ther-
apy in ESCC patients who received first-line cisplatin or
docetaxel-based treatments.
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